dc.creator | De Vleeschauwer, A. R. | en |
dc.creator | Baras, B. | en |
dc.creator | Kyriakis, C. S. | en |
dc.creator | Jacob, V. | en |
dc.creator | Planty, C. | en |
dc.creator | Giannini, S. L. | en |
dc.creator | Mossman, S. | en |
dc.creator | Van Reeth, K. | en |
dc.date.accessioned | 2015-11-23T10:25:15Z | |
dc.date.available | 2015-11-23T10:25:15Z | |
dc.date.issued | 2012 | |
dc.identifier | 10.1016/j.vaccine.2012.06.028 | |
dc.identifier.issn | 0264410X | |
dc.identifier.uri | http://hdl.handle.net/11615/26950 | |
dc.description.abstract | We used the pig model of influenza to examine the efficacy of an AS03 A-adjuvanted split H5N1 (A/Indonesia/05/2005) vaccine against challenge with a low pathogenic (LP) H5N1 avian influenza (AI) virus (duck/Minnesota/1525/1981) with only 85% amino acid homology in its HA1. Influenza seronegative pigs were vaccinated twice intramuscularly with adjuvanted vaccine at 3 antigen doses, unadjuvanted vaccine or placebo. All pigs were challenged 4 weeks after the second vaccination and euthanized 2 days later. After 2 vaccinations, all pigs in the adjuvanted vaccine groups had high hemagglutination inhibiting (HI) antibody titers to the vaccine strain (160-640), and lower antibody titers to the A/Vietnam/1194/04 H5N1 strain and to 2 LP H5 viruses with 90-91% amino acid homology to the vaccine strain (20-160). Eight out of 12 pigs had HI titers (10-20) to the challenge virus immediately before challenge. Neuraminidase inhibiting antibodies to the challenge virus were detected in most pigs (7/12) and virus neutralizing antibodies in all pigs. There was no antigen-dose dependent effect on the antibody response among the pigs immunized with adjuvanted H5N1 vaccines. After challenge, these pigs showed a complete clinical protection, reduced lung lesions and a significant protection against virus replication in the respiratory tract. Though the challenge virus showed only moderate replication efficiency in pigs, our study suggests that AS03 A-adjuvanted H5N1 vaccine may confer a broader protection than generally assumed. The pros and cons of the pig as an H5N1 challenge model are also discussed. © 2012 Elsevier Ltd. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84864303662&partnerID=40&md5=c77f8529f4befe3134191a5048243f0b | |
dc.subject | Animal models for influenza | en |
dc.subject | AS03 A adjuvant | en |
dc.subject | Cross-protection | en |
dc.subject | Efficacy | en |
dc.subject | H5N1 avian influenza virus | en |
dc.subject | Pigs | en |
dc.subject | Prepandemic vaccine | en |
dc.subject | adjuvant | en |
dc.subject | amino acid | en |
dc.subject | antibody | en |
dc.subject | as 03a | en |
dc.subject | hemagglutination inhibiting antibody | en |
dc.subject | influenza H5N1 split virion vaccine | en |
dc.subject | neutralizing antibody | en |
dc.subject | placebo | en |
dc.subject | sialidase inhibiting antibody | en |
dc.subject | swine influenza vaccine | en |
dc.subject | unclassified drug | en |
dc.subject | immunological adjuvant | en |
dc.subject | influenza vaccine | en |
dc.subject | animal cell | en |
dc.subject | animal experiment | en |
dc.subject | animal model | en |
dc.subject | animal tissue | en |
dc.subject | antibody response | en |
dc.subject | antibody titer | en |
dc.subject | article | en |
dc.subject | avian influenza | en |
dc.subject | controlled study | en |
dc.subject | drug efficacy | en |
dc.subject | hemagglutination inhibition test | en |
dc.subject | Influenza virus A H5N1 | en |
dc.subject | nonhuman | en |
dc.subject | priority journal | en |
dc.subject | respiratory system | en |
dc.subject | sequence homology | en |
dc.subject | virus inhibition | en |
dc.subject | virus replication | en |
dc.subject | virus strain | en |
dc.subject | animal | en |
dc.subject | cellular immunity | en |
dc.subject | disease model | en |
dc.subject | human | en |
dc.subject | immunology | en |
dc.subject | influenza | en |
dc.subject | lung | en |
dc.subject | pathogenicity | en |
dc.subject | pathology | en |
dc.subject | swine | en |
dc.subject | virology | en |
dc.subject | Adjuvants, Immunologic | en |
dc.subject | Animals | en |
dc.subject | Antibodies, Neutralizing | en |
dc.subject | Disease Models, Animal | en |
dc.subject | Hemagglutination Inhibition Tests | en |
dc.subject | Humans | en |
dc.subject | Immunity, Cellular | en |
dc.subject | Influenza A Virus, H5N1 Subtype | en |
dc.subject | Influenza Vaccines | en |
dc.subject | Influenza, Human | en |
dc.subject | Sus scrofa | en |
dc.title | Efficacy of an AS03 A-adjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs | en |
dc.type | journalArticle | en |